PMID- 27393417
OWN - NLM
STAT- MEDLINE
DCOM- 20170828
LR  - 20220316
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 57
DP  - 2016 Nov
TI  - Expression of amphiregulin in mucoepidermoid carcinoma of the major salivary 
      glands: a molecular and clinicopathological study.
PG  - 37-44
LID - S0046-8177(16)30136-8 [pii]
LID - 10.1016/j.humpath.2016.06.016 [doi]
AB  - In mucoepidermoid carcinoma (MEC), CRTC1-MAML2 fusion indicates a favorable 
      prognosis. Amphiregulin (AREG), an epidermal growth factor receptor (EGFR) 
      ligand, has been shown to be a downstream target of CRTC1-MAML2 fusion, and to 
      play a role in tumor growth and survival in CRTC1-MAML2-positive MEC cell lines. 
      The aim of this study was to characterize the AREG and EGFR expression in the 
      fusion-positive and fusion-negative MEC of the major salivary gland. The AREG and 
      EGFR expression were studied by immunochemistry in 33 MEC cases of the major 
      salivary glands. CRTC1-MAML2 fusion was tested by reverse-transcription 
      polymerase chain reaction (23 CRTC1-MAML2 fusion-positive, 10 fusion-negative). 
      Of 23 fusion-positive cases, AREG and EGFR overexpression were detected in 17 
      (73.9%) and 14 (60.9%) cases, respectively. Of 10 fusion-negative cases, AREG and 
      EGFR overexpression were detected in 1 (10%) and 3 (30.0%) cases, respectively. 
      There was a positive correlation between CRTC1-MAML2 fusion and AREG 
      overexpression (P < .01), but not between CRTC1-MAML2 fusion and EGFR 
      overexpression. The AREG overexpression was associated with a longer disease-free 
      survival of the MEC patients (P = .042), but EGFR overexpression was not. In this 
      study, we showed that AREG overexpression was detected more frequently in the 
      CRTC1-MAML2 fusion-positive tumors than in fusion-negative tumors. Detection of 
      AREG expression may be useful for identifying CRTC1-MAML2-positive MECs and as a 
      marker for favorable prognosis.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Shinomiya, Hitomi
AU  - Shinomiya H
AD  - Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate 
      School of Medicine, Kobe, 650-0017, Japan. Electronic address: 
      takami@med.kobe-u.ac.jp.
FAU - Ito, Yohei
AU  - Ito Y
AD  - Department of Pathology and Molecular Diagnostics, Nagoya City University 
      Postgraduate School of Medical Sciences, Nagoya, 467-8601, Japan; Department of 
      Maxillofacial Surgery, Aichi-Gakuin University School of Dentistry, Nagoya, 
      464-8651, Japan.
FAU - Kubo, Mie
AU  - Kubo M
AD  - Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate 
      School of Medicine, Kobe, 650-0017, Japan.
FAU - Yonezawa, Koichiro
AU  - Yonezawa K
AD  - Department of Otorhinolaryngology, Hyogo Cancer Center, Akashi, 673-8558, Japan.
FAU - Otsuki, Naoki
AU  - Otsuki N
AD  - Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate 
      School of Medicine, Kobe, 650-0017, Japan.
FAU - Iwae, Shigemichi
AU  - Iwae S
AD  - Department of Otorhinolaryngology, Hyogo Cancer Center, Akashi, 673-8558, Japan.
FAU - Inagaki, Hiroshi
AU  - Inagaki H
AD  - Department of Pathology and Molecular Diagnostics, Nagoya City University 
      Postgraduate School of Medical Sciences, Nagoya, 467-8601, Japan.
FAU - Nibu, Ken-Ichi
AU  - Nibu KI
AD  - Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate 
      School of Medicine, Kobe, 650-0017, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160705
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (AREG protein, human)
RN  - 0 (Amphiregulin)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CRTC1 protein, human)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MAML2 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Aged
MH  - Amphiregulin/*metabolism
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Biopsy
MH  - Carcinoma, Mucoepidermoid/genetics/*metabolism/pathology/surgery
MH  - Cell Line, Tumor
MH  - DNA-Binding Proteins/genetics
MH  - Disease-Free Survival
MH  - ErbB Receptors/metabolism
MH  - Female
MH  - Gene Fusion
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Nuclear Proteins/genetics
MH  - Predictive Value of Tests
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Salivary Gland Neoplasms/genetics/*metabolism/pathology/surgery
MH  - Time Factors
MH  - Trans-Activators
MH  - Transcription Factors/genetics
MH  - Treatment Outcome
OTO - NOTNLM
OT  - AREG
OT  - CRTC1-MAML2
OT  - EGFR
OT  - Mucoepidermoid carcinoma
OT  - Prognosis
EDAT- 2016/10/25 06:00
MHDA- 2017/08/29 06:00
CRDT- 2016/07/10 06:00
PHST- 2016/02/18 00:00 [received]
PHST- 2016/06/03 00:00 [revised]
PHST- 2016/06/29 00:00 [accepted]
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/08/29 06:00 [medline]
PHST- 2016/07/10 06:00 [entrez]
AID - S0046-8177(16)30136-8 [pii]
AID - 10.1016/j.humpath.2016.06.016 [doi]
PST - ppublish
SO  - Hum Pathol. 2016 Nov;57:37-44. doi: 10.1016/j.humpath.2016.06.016. Epub 2016 Jul 
      5.